NASDAQ · PTGX
Protagonist Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PTGX: Nov 5, 2026
Protagonist Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $2.58. The reported EPS for the same quarter last year was $-0.62.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $2.58 | $3.27 | $2.21 | 4 |
| Dec 2026 | $-0.38 | $0.45 | $-0.90 | 4 |
| Mar 2027 | $-0.75 | $-0.61 | $-0.88 | 2 |
| Jun 2027 | $-0.52 | $-0.16 | $-0.89 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
BNK Invest · Zacks · Fintel · RTTNews- BNK Invest · Oct 29, 10:52 AM EDTNoteworthy ETF Outflows: IJT, PTGX, VSAT, TGTXLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P Small-Cap 600 Growth ETF (Symbol: IJT) where we have detected an approximate $180.4 million dollar outflow — that's a 2.4% decrease
- Zacks · Oct 29, 9:00 AM EDTProtagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings GrowthProtagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 29, 8:50 AM EDTWhy Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- Zacks · Oct 28, 8:55 AM EDTWall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Zacks · Oct 23, 8:37 AM EDTJ&J Stock Reclaims 50-Day SMA: Is it Time to Buy, Sell or Hold?J&J stock reclaims its 50-day SMA, but falling earnings estimates, a premium valuation and MedTech weakness raise questions about its near-term outlook.
- BNK Invest · Oct 21, 10:56 AM EDTNotable ETF Outflow Detected – SLYG, PTGX, RHP, TGTXLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P 600 Small Cap Growth ETF (Symbol: SLYG) where we have detected an approximate $145.6 million dollar outflow — that's a 3.
- Zacks · Oct 15, 11:00 AM EDTProtagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should KnowProtagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- BNK Invest · Oct 13, 10:49 AM EDTNotable ETF Outflow Detected – SPSM, PTGX, MXL, ESILooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR Portfolio S&P 600 Small Cap ETF (Symbol: SPSM) where we have detected an approximate $112.2 million dollar outflow — that's a
- Fintel · Oct 12, 12:08 PM EDTUBS Initiates Coverage of Protagonist Therapeutics with Buy RatingFintel reports that on October 12, 2026, UBS initiated coverage of Protagonist Therapeutics (NASDAQGM:PTGX) with a Buy recommendation.Protagonist Therapeutics, Inc., based in the United States, operates within the biotechnology industry, focusing significantly on developing pepti
- Zacks · Sep 18, 9:05 AM EDTJ&J Up 18% in Three Months: Buy, Sell or Hold the Stock?JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.
- BNK Invest · Sep 17, 10:48 AM EDTNoteworthy ETF Outflows: IJT, FORM, PTGX, RHPLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P Small-Cap 600 Growth ETF (Symbol: IJT) where we have detected an approximate $122.4 million dollar outflow — that's a 1.5% decrease
- RTTNews · Sep 11, 11:45 AM EDTNew FDA Drug Approvals – August 2026(RTTNews) – The U.S. Food and Drug Administration (FDA) granted approval to 13 drugs last month, comprising both new drug approvals and expanded indications for previously approved therapies.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Protagonist Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.